Feature

Research Reports

Optimizing Patient-Provider Communication in Patients With Amyloidosis Using a Virtual Platform

11/15/2022

Vaishali Sanchorawala , MD;

Lisa Mendelson , MSN;

Adam Sodowick , BA;

Isabelle Lousada , MA;

Arabella Sykes , BSc;

Jason Shore , MBA;

Sabrina Rebello , MPH;

Kristen Hsu , BSc;

The authors present a study that aimed to investigate the real-world use of a virtual platform, Amyloidosis Appointment Companion, in improving communication between patients with amyloidosis and their providers.

The authors present a study that...

11/15/2022

Journal of Clinical Pathways

Research Reports

08/15/2022

Kathryn Christensen , MD, MS;

Timothy Dollear , MD, MS;

Eric Gratias , MD, FAAP;

Christopher Linkimer , CPA;

Margaret Rausa , PharmD;

Nick Andrews , PharmD;

Stephen Hamilton , MD;

Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.

Dr Hamilton and colleagues...

08/15/2022

Journal of Clinical Pathways

Research Reports

Phase II: A Value-Based Collaborative Care Model by Payers, Providers, and Pharma

08/11/2022

Mary Aikins , RN, CCM;

Lili Brillstein , MPH;

Michael Udwin , MD, FACOG;

Eric McCulley , RN;

A group of stakeholders determined several key challenges to delivering care to patients with psoriatic arthritis, and highlighted several points that should be considered when building a value-based care model for this patient group.

A group of stakeholders...

08/11/2022

Journal of Clinical Pathways

Research Reports

The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia in the United States: A Cost of Care and Budget Impact Model of Venetoclax Plus Obinutuzumab Sequences

06/21/2022

Matthew S. Davids , MD, MMSc;

Mazyar Shadman , MD, MPH;

Beenish S. Manzoor , PhD, MPH;

Kavita Sail , PhD;

Arliene Ravelo , MPH;

Fang Han ;

Sheila Shapouri , MS;

Nisha C. Hazra , PhD, MSc;

Annie Guerin , MS;

Honghao Fang , MSc;

Dr Davids and colleagues estimated the total cumulative costs per patient of treatment sequences for adults with chronic lymphocytic leukemia, with and without deletion 17p, as well as the budget impact of introducing sequences with...

Dr Davids and colleagues...

06/21/2022

Journal of Clinical Pathways

Research Reports

Quality Measure Concepts to Fill Gaps in Assessing Oral Oncolytic Adherence: A Multistakeholder Measurement Strategy

06/16/2022

Sandra Kurtin , PhD;

Leigh Boehmer , PharmD;

Michael Reff , RPh, MBA;

Rachael Peroutky , MSPH;

David Blaisdell , BA;

Shelley Fuld Nasso , MPP;

Katie Schultz , MSPH;

Tom Valuck , MD, JD;

A multistakeholder workgroup of oncology and quality measurement experts explored gaps in quality measures focused on oral oncolytic adherence and identified, prioritized, and refined measure concepts for further development.

A multistakeholder workgroup of...

06/16/2022

Journal of Clinical Pathways

From the Field

Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer

05/19/2022

Junxin Shi , PhD;

Yiqiong Xie , PhD, MPH;

Katrine L. Wallace , PhD;

Robert Reid , MD;

Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.

Dr Wallace and colleagues...

05/19/2022

Journal of Clinical Pathways

From the Field

Real-World Characteristics and Outcomes of Patients With Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Treated With First-Line Bendamustine + Rituximab

04/20/2022

Erica DiMaria , MD;

David Susman ;

Derek Nay , MD;

Rouslan Kotchetkov , MD, PhD;

Lauren Gerard , MD;

Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.

Dr Kotchetkov and colleagues...

04/20/2022

Journal of Clinical Pathways

From the Field

Incidence and Cost of Radical Prostatectomy and Radiotherapy for NCCN Low-risk Prostate Cancer in Utah

03/16/2022

Bryan Crawford ;

Jesse Gygi ;

Brandon Barney , MD;

Libby Petersen ;

McKenzie Bell ;

Zoya Sandhu ;

David Gill , MD;

Jonathan Tward , MD;

Jessica Baumgartner ;

David Gill, MD , and colleagues analyzed rates of treatment for men with low-risk disease who were treated at either The Huntsman Cancer Institute or Intermountain Healthcare facilities, and modeled the costs associated with the presumptive...

David Gill, MD , and colleagues...

03/16/2022

Journal of Clinical Pathways

From the Field

Streamlining Institutional Pathway Processes: The Development and Implementation of a Pathology Molecular Consult to Facilitate Convenient and Efficient Ordering, Fulfillment, and Reporting for Tissue Molecular Tests

02/15/2022

Sharad Mathur , MD;

Janet Barrett ;

Michael Goodman , MD;

Maryam Abdo , MBChB;

Susie Willis ;

Linda Verkruyse , MD;

Joseph Modzelewski ;

Robert Hoyt , MD;

Hanan Elsarraj , MD;

Daniel Mettman , MD;

Daniel Mettman, MD, and colleagues detail the work of two mid-sized VA medical centers in collectively developing and implementing a consult process as part of their oncology clinical pathways to standardize ordering, fulfillment, and...

Daniel Mettman, MD, and...

02/15/2022

Journal of Clinical Pathways

Research Reports

Factors Associated With Poor Outcomes in Patients who Receive Cancer Directed Therapy at the End of Life

02/15/2022

Megan Wall , MS;

Ila M. Saunders , PharmD, BCOP;

Janine Martino , PharmD, BCOP, APh;

Alison Wall , MS;

Shanna Block , PharmD, BCOP;

Rabia S. Atayee , PharmD, BCPS;

Katherine Medley , PharmD;

Yasmine Anouty , PharmD;

Carolyn Mulroney , MD;

Yasmine Anouty, PharmD, and colleagues discern factors that may be associated with poor outcomes in adult patients who received intravenous cancer-directed therapy in the last 30 days of life.

Yasmine Anouty, PharmD, and...

02/15/2022

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Feature

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products